Medtronic

2391 articles about Medtronic

• Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years

  10/24/2023

  Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced four-year results from the Evolut Low Risk Trial.

• Medtronic receives FDA approval for extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest

  10/23/2023

  Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest (SCA).

• Medtronic Diabetes announces CE Mark for new Simplera™ CGM with disposable all-in-one design

  9/21/2023

  Medtronic plc, a global leader in healthcare technology, announced CE Mark approval for its new all-in-one, disposable Simplera™ continuous glucose monitor featuring a simple, two-step insertion process.

• FluidAI Medical Teams Up with Medtronic for Remote Monitoring via DIGITAL's Continuous Connected Patient Care Project

  9/14/2023

  FluidAI Medical, a leading artificial intelligence (AI) startup and developer of the Stream™ Platform for post-surgical monitoring, has announced a strategic partnership with Medtronic Canada ULC, a prominent subsidiary of the global healthcare technology company, Medtronic PLC.

• Medtronic receives CE Mark approval for Inceptiv™ spinal cord stimulator with closed-loop sensing to treat chronic pain

  8/25/2023

  Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received CE (Conformité Européenne) Mark approval for its Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS).

• Medtronic issues statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

  8/24/2023

  Medtronic announced the outcome of the U.S. Food & Drug Administration Circulatory System Devices Panel meeting to review data presented in support of the Medtronic Symplicity Spyral™ Renal Denervation System.

• Medtronic reports first quarter fiscal 2024 financial results

  8/22/2023

  Medtronic plc announced financial results for its first quarter of fiscal year 2024, which ended July 28, 2023.

• Medtronic to participate in upcoming September 2023 investor conferences

  8/22/2023

  Medtronic plc, a global leader in healthcare technology, confirmed its participation in the following upcoming investor conferences.

• Medtronic announces cash dividend for second quarter of fiscal year 2024

  8/17/2023

  The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 17, 2023, approved an increase in the company's cash dividend for the second quarter of fiscal year 2024 versus the prior year, raising the quarterly amount to $0.69 per ordinary share.

• Medtronic to announce financial results for its first quarter of fiscal year 2024

  8/8/2023

  Medtronic plc, a global leader in healthcare technology, announced that it will report financial results for its first quarter of fiscal year 2024 on Tuesday, August 22, 2023.

• Medtronic Board appoints Greg Lewis as new Director

  6/26/2023

  Medtronic announced today that its Board of Directors appointed Greg Lewis , Senior Vice President and Chief Financial Officer at Honeywell, to the Board.

• Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

  6/23/2023

  Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system.

• Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions

  6/12/2023

  Medtronic plc, a global leader in medical technology, announced its participation in the upcoming American Diabetes Association's 83rd Scientific Sessions in San Diego on Jun. 23-26, 2023.

• Medtronic names Ken Washington new Chief Technology and Innovation Officer

  6/1/2023

  Medtronic plc announced that Ken Washington, Ph.D., has been appointed Medtronic Chief Technology and Innovation Officer.

• Medtronic to acquire wearable insulin patch maker EOFlow

  5/25/2023

  Medtronic plc, a global leader in healthcare technology, announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch® device — a tubeless, wearable and fully disposable insulin delivery device.

• Medtronic reports full year and fourth quarter fiscal 2023 financial results; announces dividend increase

  5/25/2023

  Medtronic plc announced financial results for its fourth quarter and fiscal year 2023, which ended April 28, 2023.

• Medtronic Extravascular ICD global clinical trial results reinforce device safety and effectiveness

  5/20/2023

  Medtronic plc, a global leader in healthcare technology, announced longer-term follow-up results of its investigational EV ICD™ System, designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest.

• Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

  5/16/2023

  Medtronic plc (NYSE: MDT) today announced its AccuRhythm™ AI algorithm technology is the winner of the 7th annual MedTech Breakthrough Awards program as the "Best New Monitoring Solution."

• Medtronic to announce financial results for its fourth quarter and full fiscal year 2023

  5/11/2023

  Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2023 on Thursday, May 25, 2023.

• Medtronic receives FDA approval for its next generation Micra leadless pacing systems

  5/1/2023

  Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniaturized, leadless pacemakers.